Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

NCT00858403 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Lung Cancer

Interventions

DRUG: Dasatinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]